Pharmaceutical Products

The Ares Specialty Healthcare Fund is a specialized direct‑lending vehicle managed by Ares Management, formed to provide flexible capital solutions to companies operating across the specialty healthcare ecosystem. It focuses on industries such as pharmaceuticals, biotechnology, medical technologies and diagnostics, specialist healthcare services and healthcare IT where companies often face constraints accessing traditional bank financing or need transformational capital. The fund is structured to invest across the capital structure — from first‑ and second‑lien senior secured loans, to mezzanine debt, preferred equity and minority equity stakes — enabling the team to tailor solutions to companies undergoing growth or transformation. It targets businesses in North America and Europe and is backed by a dedicated investment team and industry advisory board with deep healthcare operating expertise. Recognising enduring structural trends — an aging population, innovation in diagnostics and medtech, increasing digitalisation of healthcare and shifting service models — the fund seeks to invest in companies with resilient demand and growth potential. It aims to deliver both defensive characteristics (i.e., non‑cyclical healthcare demand) and meaningful upside from innovation and transformation in the healthcare value chain. By partnering with firms across the healthcare spectrum — from device manufacturers and diagnostics players to niche specialty services and healthcare IT platforms — the fund aims to fill a financing gap and support businesses that are scaling, executing roll‑ups or transforming their offerings. The strategy leverages Ares’ broader credit platform and healthcare expertise to structure creative, non‑dilutive capital solutions in an increasingly competitive healthcare financing environment.

BluePeak Private Capital Fund II (BPCF II) is a pan-African private credit fund launched by BluePeak Private Capital, an alternative asset management firm established in 2019. The fund aims to raise $250 million to provide flexible credit solutions to underserved mid-sized businesses across Africa, addressing the persistent financing gap that hinders their growth. BPCF II focuses on delivering impact-driven investments while offering investors superior risk-adjusted returns. The fund targets strategic sectors such as manufacturing, pharmaceuticals, logistics, and financial services—industries pivotal to deepening local value chains and fostering industrial clusters. With a strong emphasis on gender inclusion, BPCF II is 2X Challenge qualified, promoting women's economic empowerment as a core objective. The fund integrates sustainability considerations throughout its investment process, prioritizing resilience, inclusive growth, and long-term value creation. In its first close, BPCF II secured $80 million in commitments from leading European Development Finance Institutions (DFIs), including British International Investment (BII), FMO, Swedfund, and the Swiss Investment Fund for Emerging Markets (SIFEM). These commitments underscore the DFIs' confidence in BluePeak's strategy to combine performance with impact, mobilizing capital to Africa's underserved mid-market segment.

CVC Strategic Opportunities II is a €4.6 billion private equity fund launched in 2019 by CVC Capital Partners. It is the second fund in CVC’s long-dated investment strategy, focusing on patient capital for high-quality businesses. The fund emphasizes long-term partnerships with companies operating in low-volatility sectors and demonstrating strong cash flow generation. The strategy targets control, co-control, or significant minority stakes in companies offering essential products or services. These businesses typically have stable capital structures and consistent earnings. CVC works with portfolio companies to enhance value through operational improvements and strategic growth initiatives. The fund primarily focuses on Western Europe and North America, investing across sectors such as commercial services, pharmaceuticals, biotechnology, and manufacturing. Target companies generally have enterprise values between €1 billion and €5 billion, allowing CVC to support a broad range of sizable, stable businesses.

Columbus Innvierte Life Science I is the debut venture capital fund managed by Columbus Venture Partners, a Valencia, Spain-based life sciences investor founded in 2016 by Javier García and Damià Tormo. The fund was registered with the Spanish securities regulator CNMV (registration no. 190) and launched in April 2016 as part of Spain's Innvierte programme, a public-private co-investment initiative supporting early-stage innovation. The fund raised EUR 42 million and had an investment period running from 2016 to 2018, making seed and Series A investments in deep biotech and advanced therapy companies, primarily in Spain. The fund's strategy combined scientific expertise in therapeutic development with an industrial vision, targeting companies working on cell and gene therapies, AAV vector manufacturing, and other disruptive life sciences platforms. Columbus Venture Partners brought a distinctive approach of investing in both product development and the manufacturing infrastructure required to scale these technologies, thereby shortening time to exit. The geographic focus was Spain with international reach, co-investing alongside specialist international and corporate venture funds. The fund built a portfolio of eight investments and has since generated exceptional returns through landmark exits. Viralgen Vector Core was sold to Bayer in 2020 in a transaction valued at approximately EUR 4 billion. Vivet Therapeutics was acquired by Pfizer for an upfront and option value of EUR 560 million. Aura Biosciences completed a NASDAQ IPO in 2021. Columbus Venture Partners now manages over EUR 400 million across four successive funds, establishing itself as one of Spain's leading life sciences venture capital franchises.

Columbus Life Sciences Fund IV is a venture capital fund based in Spain and managed by Columbus Venture Partners. The fund has a size of 150 million euros and it is aimed at biotechnology and pharmaceutical startups. The portfolio of companies selected for this fund will focus on disruptive treatments and industrial development, particularly in the drug development process. The fund plans to make between ten and twelve investments in total. Investments from this fund will range from three million euros to a maximum of twenty million euros over the life cycle of the company. The investment timeframe for selecting portfolio companies is up to three years, with a total period of ten years to close. The Columbus VP team, led by founders and managing partners Javier García and Damià Tormo, along with partners Julen Oyarzábal, José Mesa, and Robert Armstrong, will manage this new fund.

Forbion Growth Fund III is a late-stage life sciences growth fund managed by Forbion, a specialist European venture capital firm headquartered in Naarden, the Netherlands, with offices in Munich, Germany and Boston, United States. The fund targets later-stage biopharmaceutical companies developing novel therapies in areas of high medical need, focusing on European and North American clinical-stage assets with significant near-term catalysts. The fund is part of Forbion's Growth strategy, which provides private growth capital to clinical-stage biopharma companies, crossover financing to companies preparing for public listings, and opportunistic capital to undervalued public biopharmaceutical companies. Forbion typically leads investment rounds and secures board representation to support portfolio companies through key clinical and regulatory milestones. Therapeutic areas of focus include oncology, rare diseases, immunology, and cardiovascular and metabolic conditions. Forbion has built a substantial track record in European life sciences growth equity, with total assets under management exceeding €5 billion following the close of its latest fund vehicles. The Growth franchise, of which this fund is a part, has backed European biopharma companies including Gyroscope Therapeutics (acquired by Novartis), and has attracted institutional investors spanning Dutch pension advisors, global asset managers, pharma strategic investors, and international fund-of-funds. Forbion's in-house scientific expertise and deep European academic network underpin its ability to identify and support best-in-class clinical-stage therapeutic assets.

Forbion Growth Opportunities Fund II is a €600 million life sciences growth fund managed by Forbion, the Netherlands-based specialist venture capital firm headquartered in Naarden with offices in Munich and Boston. The fund reached its hard cap and completed its final close in April 2023 as part of a simultaneous €1.35 billion raise alongside Forbion Ventures Fund VI. New institutional investors joining the fund included Amundi and Legal & General Capital, complementing existing backers Dutch pension funds PME and PMT, Pantheon Ventures, and Eli Lilly and Company. The fund focuses on later-stage European biopharmaceutical companies developing novel therapies in areas of significant unmet medical need, with selective exposure to North American crossover opportunities. Forbion leads investments of up to €70 million per company, taking board seats and providing active support through clinical milestones and liquidity events. Primary investment areas span oncology, rare diseases, immunology, and other clinical-stage therapeutic categories. As of its final close in April 2023, the fund had already made four portfolio investments, demonstrating rapid capital deployment aligned with Forbion's established deal pipeline. Forbion Growth Opportunities Fund II is the second vehicle in the Growth Opportunities franchise, following Fund I (€360 million, 2021). The strategy reflects Forbion's systematic approach to late-stage biopharma investing, leveraging scientific expertise, an extensive network in European academic institutions, and privileged access to global crossover investors. The institutional LP base spanning pan-European asset managers, strategic pharma investors, fund-of-funds, and pension allocators underscores strong demand for European life sciences growth equity.

Forbion Growth Opportunities Fund III is a €1.2 billion late-stage life sciences growth fund managed by Forbion, one of Europe's leading specialist venture capital firms, headquartered in Naarden, the Netherlands, with additional offices in Munich, Germany and Boston, United States. The fund reached its hard cap in October 2024, marking Forbion's largest single fundraise and pushing the firm's total assets under management beyond €5 billion across more than 128 historical investments and a team of over 30 investment professionals. The fund backs later-stage biopharmaceutical companies in Europe and North America that are advancing novel therapies in areas of high medical need. Forbion deploys three integrated strategies: providing private growth capital to clinical-stage biopharma companies, offering crossover financing to companies approaching public listings, and deploying capital opportunistically into undervalued public biopharma assets. Investment sizes reach up to €70 million per company, with Forbion typically leading rounds and taking board representation. Therapeutic areas include oncology, rare diseases, immunology, neurology, and cardiovascular and metabolic conditions. The fund targets a portfolio of approximately 15 companies. Forbion Growth Opportunities Fund III builds on Fund I (€360M, April 2021) and Fund II (€600M, April 2023), both of which achieved their hard caps. Prior portfolio companies have included Gyroscope Therapeutics, acquired by Novartis. Institutional investors include Dutch pension advisor MN. The fund's thesis reflects Forbion's conviction that Europe's clinical-stage biopharma ecosystem, combined with access to global crossover markets, offers differentiated risk-adjusted returns for sophisticated life sciences investors.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

Gyrus Capital, a Geneva-based private equity firm specializing in healthcare and sustainability sectors, has successfully closed a €700 million single-asset continuation fund dedicated to Essential Pharma. Essential Pharma is an international specialty pharmaceutical group focused on providing access to low-volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation fund was led by AlpInvest Partners, a subsidiary of Carlyle Global Investment Solutions, with significant participation from StepStone Group and other new and existing investors. Both Gyrus Capital and Essential Pharma's management team have made meaningful reinvestments in the fund. This transaction provides Essential Pharma with substantial additional capital to expand its diversified portfolio of established and rare disease medicines through acquisitions and development strategies. The company operates globally in more than 70 countries, supplying over 300 products across multiple therapeutic areas.

The $750 million private equity multi-asset continuation fund announced by Hildred Capital is focused on healthcare and specializes in partnering with middle-market companies. The fund was structured to align the interests of the general partnership and limited partners, with the co-founders rolling over 100% of their economic interests into the continuation fund. Limited partners had the option to roll all, sell all, or sell a portion of their interests and roll a portion into the continuation fund. This fund aims to provide additional committed capital for companies to execute organic growth initiatives, pursue strategic acquisitions, and continue to drive operating leverage. It has generated significant liquidity and attractive returns for selling limited partners while also providing new investors with the opportunity to participate over time in the appreciation of strong and growing companies.

Inveready Innvierte Biotech II is a Spanish venture capital fund managed by Inveready, one of Spain's most active alternative investment firms managing over €2.2 billion in assets across venture capital and private equity strategies. Established in 2013 and structured as a Sociedad de Capital Riesgo (S.C.R.) under CNMV regulation, the fund was co-sponsored under the Spanish government's Innvierte program, which promoted private investment in innovative companies by matching institutional capital with public co-investment. The fund invested across a portfolio of 22 life sciences companies, with 94% of capital allocated to Spanish companies, making it one of the most concentrated dedicated biotech venture funds in Spain during its investment period.Inveready Innvierte Biotech II deployed capital at the early stages of the life sciences value chain, focusing on companies at the seed and Series A stage across drug development (47% of the portfolio), over-the-counter products, medical services, and digital health. The fund adopted a multi-stage strategy, following companies from initial investment through clinical development and commercialization. The fund management team was led by Sara Secall, Roger Piqué, and Josep Maria Echarri, who brought deep sector expertise in pharmaceutical sciences, biotech commercialization, and venture capital to the portfolio management process. The fund's geographic focus on Spain allowed it to build a concentrated exposure to the domestic biotech ecosystem at a formative period in its development.Inveready Innvierte Biotech II was fully divested, delivering a 4.3x return on invested capital to its shareholders — making it the fourth venture capital fund Inveready has successfully exited, all with markedly positive results. Notable exits include Avizorex, the first venture-backed Spanish company to complete the full drug development cycle and receive U.S. marketing authorization from Alcon (world leader in ophthalmology) for an ophthalmic drug; the sale of stakes in Reva Health and Zera; and the IPO and subsequent divestment of Edesa Biotech on Nasdaq and Atrys Health on the Spanish Mercado Continuo. Portfolio companies created over 2,500 direct jobs — 57% held by women — and attracted more than €500 million in follow-on investment, with over €200 million allocated to R&D activities.

Iron Wolf Capital has announced the first close of its second fund, securing $32.7 million with a target of $109 million. The fund focuses on early-stage investments in deeptech and AI startups across the Baltic region and its diaspora. Initial investments range from $545,000 to $2.18 million, with the firm often leading or co-leading funding rounds. The firm is recognized as one of the most active investors in the Baltics, having supported over 20 companies in the past five years. Its portfolio spans various sectors, including robotics, photonics, AI-driven education technology, pharmaceuticals, and climate technology. Iron Wolf Capital emphasizes backing exceptional founders with global ambitions and disruptive technologies. Beyond capital, Iron Wolf Capital contributes to the ecosystem through initiatives like the Baltic Deep Tech Report and the Deep Tech Breakfast Series, fostering collaboration and growth within the region's innovation landscape.

Linden Capital Partners, a Chicago-based private equity firm specializing in healthcare, has successfully closed its sixth buyout fund, Linden Capital Partners VI, at $5.4 billion. This marks a major milestone, surpassing its $4.5 billion target and initial $5.0 billion hard cap. The fund secured $5.2 billion in LP commitments from investors in more than 20 countries, along with a $200 million general partner commitment. Fund VI will continue Linden’s long-standing strategy of investing in middle-market healthcare companies, with a focus on services, products, and distribution segments. The firm brings a disciplined approach to value creation, combining deep operational expertise, tailored growth strategies, and a unique human capital model to support long-term success. The fund's investor base includes major institutional investors such as the New York State Teachers’ Retirement System, Texas County & District Retirement System, Louisiana State Employees’ Retirement System, Sacramento County Employees’ Retirement System, and Fairfax County Educational Employees’ Supplementary Retirement System. The oversubscribed fund closed in under nine months, highlighting strong investor demand and Linden’s leadership in healthcare investing.